Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


DOI: 10.1530/eje.0.1330133
European Journal of Endocrinology, Vol 133, Issue 2, 133-144
Copyright © 1995 by European Society of Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gicquel, C.
Right arrow Articles by Le Bouc, Y.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Gicquel, C.
Right arrow Articles by Le Bouc, Y.

Recent advances in the pathogenesis of adrenocortical tumours

Christine Gicquel, Xavier Bertagna and Yves Le Bouc

Steroid-secreting human adrenocortical tumours are rare. Their incidence is estimated to be 0.2/100 000 per year (1). Benign adenomas and the malignant carcinomas are about equally frequent (2–4). The most common clinical presentation is that of Cushing's syndrome with or without association virilism. Adenomas responsible for primary aldosteronism (Conn's syndrome) are less frequent, and oestrogen-producing tumours—usually malignant— are rare (5). Approximately half the malignant adrenocortical cancers secrete mainly biosynthetic precursors with diminished bioactivity: their diagnosis is often delayed and they may thus be huge when discovered. More often sporadic, adrenocortical tumours can also combine with rare congenital syndromes including Beckwith-Wiedemann syndrome (6), the McCune-Albright syndrome (7) or Li-Fraumeni syndrome (8).

Because there are no absolute clinical, biological, anatomical or even histological criteria, in many cases the benign or malignant nature of a localized tumour cannot be strictly asserted. Malignant adrenocortical tumours have a very poor prognosis (2–4, 9–15): mean survival




This article has been cited by other articles:


Home page
Endocr Relat CancerHome page
R. Libe, A. Fratticci, and J. Bertherat
Adrenocortical cancer: pathophysiology and clinical management
Endocr. Relat. Cancer, March 1, 2007; 14(1): 13 - 28.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. N. West, G. A. Neale, S. Pounds, B. C. Figueredo, C. Rodriguez Galindo, M. A. D. Pianovski, A. G. Oliveira Filho, D. Malkin, E. Lalli, R. Ribeiro, et al.
Gene Expression Profiling of Childhood Adrenocortical Tumors
Cancer Res., January 15, 2007; 67(2): 600 - 608.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. Lampron, I. Bourdeau, P. Hamet, J. Tremblay, and A. Lacroix
Whole Genome Expression Profiling of Glucose-Dependent Insulinotropic Peptide (GIP)- and Adrenocorticotropin-Dependent Adrenal Hyperplasias Reveals Novel Targets for the Study of GIP-Dependent Cushing's Syndrome
J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3611 - 3618.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
R. Libe and J. Bertherat
Molecular genetics of adrenocortical tumours, from familial to sporadic diseases
Eur. J. Endocrinol., October 1, 2005; 153(4): 477 - 487.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
F. Tissier, C. Cavard, L. Groussin, K. Perlemoine, G. Fumey, A.-M. Hagnere, F. Rene-Corail, E. Jullian, C. Gicquel, X. Bertagna, et al.
Mutations of {beta}-Catenin in Adrenocortical Tumors: Activation of the Wnt Signaling Pathway Is a Frequent Event in both Benign and Malignant Adrenocortical Tumors
Cancer Res., September 1, 2005; 65(17): 7622 - 7627.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A.-M. Lefrancois-Martinez, J. Bertherat, P. Val, C. Tournaire, N. Gallo-Payet, D. Hyndman, G. Veyssiere, X. Bertagna, C. Jean, and A. Martinez
Decreased Expression of Cyclic Adenosine Monophosphate-Regulated Aldose Reductase (AKR1B1) Is Associated with Malignancy in Human Sporadic Adrenocortical Tumors
J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 3010 - 3019.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M.-H. Bernard, S. Sidhu, N. Berger, J.-L. Peix, D. J. Marsh, B. G. Robinson, V. Gaston, Y. Le Bouc, and C. Gicquel
A Case Report in Favor of a Multistep Adrenocortical Tumorigenesis
J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 998 - 1001.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. Gicquel, X. Bertagna, V. Gaston, J. Coste, A. Louvel, E. Baudin, J. Bertherat, Y. Chapuis, J.-M. Duclos, M. Schlumberger, et al.
Molecular Markers and Long-Term Recurrences in a Large Cohort of Patients with Sporadic Adrenocortical Tumors
Cancer Res., September 1, 2001; 61(18): 6762 - 6767.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
A. Lacroix, N. N'Diaye, J. Tremblay, and P. Hamet
Ectopic and Abnormal Hormone Receptors in Adrenal Cushing's Syndrome
Endocr. Rev., February 1, 2001; 22(1): 75 - 110.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
F. Wilkin, N. Gagné, J. Paquette, L. L. Oligny, and C. Deal
Pediatric Adrenocortical Tumors: Molecular Events Leading to Insulin-Like Growth Factor II Gene Overexpression
J. Clin. Endocrinol. Metab., May 1, 2000; 85(5): 2048 - 2056.
[Abstract] [Full Text]


Home page
HypertensionHome page
P. Mulatero, D. Schiavone, F. Fallo, F. Rabbia, C. Pilon, L. Chiandussi, L. Pascoe, and F. Veglio
CYP11B2 Gene Polymorphisms in Idiopathic Hyperaldosteronism
Hypertension, March 1, 2000; 35(3): 694 - 698.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
C. Pilon, M. Pistorello, A. Moscon, G. Altavilla, U. Pagotto, M. Boscaro, and F. Fallo
Inactivation of the p16 Tumor Suppressor Gene in Adrenocortical Tumors
J. Clin. Endocrinol. Metab., August 1, 1999; 84(8): 2776 - 2779.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
L. Barzon, C. Scaroni, N. Sonino, F. Fallo, A. Paoletta, and M. Boscaro
Risk Factors and Long-Term Follow-Up of Adrenal Incidentalomas
J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 520 - 526.
[Abstract] [Full Text]


Home page
Am. J. Pathol.Home page
R. V. Lloyd, L. A. Erickson, L. Jin, E. Kulig, X. Qian, J. C. Cheville, and B. W. Scheithauer
p27kip1: A Multifunctional Cyclin-Dependent Kinase Inhibitor with Prognostic Significance in Human Cancers
Am. J. Pathol., February 1, 1999; 154(2): 313 - 323.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
C. Gicquel, M.-L. Raffin-Sanson, V. Gaston, X. Bertagna, P.-F. Plouin, M. Schlumberger, A. Louvel, J.-P. Luton, and Y. Le Bouc
Structural and Functional Abnormalities at 11p15 Are Associated with the Malignant Phenotype in Sporadic Adrenocortical Tumors: Study on a Series of 82 Tumors
J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2559 - 2565.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. C. Latronico and G. P. Chrousos
Adrenocortical Tumors
J. Clin. Endocrinol. Metab., May 1, 1997; 82(5): 1317 - 1324.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 European Society of Endocrinology.